Page 186 - Eceptor News Today

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

New research suggests that treatment with type I interferons in the early stage of COVID-19 may supress disease progression by limiting SARS-CoV-2 in hosts.

New research examined SARS-CoV-2 and its impact on oral health and suggests that survival against the infection may be partially dependent on such factors.

Olema Pharmaceuticals, Inc. announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor antagonist and... | December 1, 2021

A team of researchers from UK and US institutions created a large panel of mAbs derived from memory B cells of convalescent Beta subjects to better understand the antigenic landscape of Beta.

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

A group led by Prof. Han Dong of Peking University School of Stomatology reported for the first time hand preaxial polydactyly in patients with tooth agenesis carrying a previously unknown mutation of low-density lipoprotein receptor-related protein 6 (LRP6).

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known as interferon, allowing for the mitigation of coronavirus disease (COVID-19) severity. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant (B.1.621, B.1.621.1) has been tagged as a Variant Being Monitored (VBM), and as of August 30, 2021, it had been detected in 39 countries.